Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S J Mather

Showing results (31-40 of 97) with videos related to

Pageof 10
Sort By:
Nuclear Medicine Communications|October 19, 2001
Hybridization and cell uptake studies with radiolabelled antisense oligonucleotidesM A Stalteri, S J Mather
Bioconjugate Chemistry|March 1, 1995
A cross-linked monoclonal antibody fragment for improved tumor targetingM A Stalteri, S J Mather
European Journal of Nuclear Medicine|May 19, 2001
General aspects of the cellular response to low- and high-LET radiationJ P Pouget, S J Mather
International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology|January 1, 1991
Diagnostic evaluation of 111In and 99mTc radiolabelled monoclonal antibodies in ovarian and colorectal cancer: correlations with surgeryM Granowska, S J Mather, K E Britton
Journal of Immunological Methods|February 11, 1987
Identification of immunoreactive monoclonal antibody fragments for improved immunoscintigraphyS J Mather, H Durbin, J Taylor-Papadimitriou
Nuclear Medicine Communications|April 26, 2002
Optimization of the small-scale synthesis of DOTA-Tyr3 -octreotideM Edreira, L Melendez-Alafort, S J Mather
Nuclear Medicine Communications|April 1, 1991
Radiolabelled monoclonal antibodies in oncology. III. RadioimmunotherapyK E Britton, S J Mather, M Granowska
Paediatric Anaesthesia|January 1, 1996
Can persistent cerebral damage be caused by hyperglycaemia?J Tuckey, S J Mather, P G Thornton
Biotechniques|February 23, 2000
Photoreduction of monoclonal antibodies for conjugation and fragmentationD Ellison, M A Stalteri, S J Mather
Nuclear Medicine Communications|January 1, 1991
Radiolabelled monoclonal antibodies in oncology. I. Technical aspectsK E Britton, M Granowska, S J Mather
Pageof 10

Showing results (31-40 of 97) with videos related to

Sort By:
Pageof 10
Nuclear Medicine Communications|October 19, 2001
Hybridization and cell uptake studies with radiolabelled antisense oligonucleotidesM A Stalteri, S J Mather
Bioconjugate Chemistry|March 1, 1995
A cross-linked monoclonal antibody fragment for improved tumor targetingM A Stalteri, S J Mather
European Journal of Nuclear Medicine|May 19, 2001
General aspects of the cellular response to low- and high-LET radiationJ P Pouget, S J Mather
International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology|January 1, 1991
Diagnostic evaluation of 111In and 99mTc radiolabelled monoclonal antibodies in ovarian and colorectal cancer: correlations with surgeryM Granowska, S J Mather, K E Britton
Journal of Immunological Methods|February 11, 1987
Identification of immunoreactive monoclonal antibody fragments for improved immunoscintigraphyS J Mather, H Durbin, J Taylor-Papadimitriou
Nuclear Medicine Communications|April 26, 2002
Optimization of the small-scale synthesis of DOTA-Tyr3 -octreotideM Edreira, L Melendez-Alafort, S J Mather
Nuclear Medicine Communications|April 1, 1991
Radiolabelled monoclonal antibodies in oncology. III. RadioimmunotherapyK E Britton, S J Mather, M Granowska
Paediatric Anaesthesia|January 1, 1996
Can persistent cerebral damage be caused by hyperglycaemia?J Tuckey, S J Mather, P G Thornton
Biotechniques|February 23, 2000
Photoreduction of monoclonal antibodies for conjugation and fragmentationD Ellison, M A Stalteri, S J Mather
Nuclear Medicine Communications|January 1, 1991
Radiolabelled monoclonal antibodies in oncology. I. Technical aspectsK E Britton, M Granowska, S J Mather
Pageof 10